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Abstract The vaccinia-related kinase (VRK) proteins are a
new group of three Ser-Thr kinases in the human kinome.
VRK proteins are upstream regulators of several transcription
factors. VRK1 phosphorylates p53 in Thr-18 within the region
of binding to mdm2 preventing their interaction. The tissue dis-
tribution of three genes is still largely unknown. In the present
report the expression of these genes was analyzed during murine
hematopoietic development. The three genes are expressed in
fetal liver and peripheral blood, with higher levels between
days 11.5 and 13.5, a time when there is a massive expansion
of liver cells, and thereafter their expression falls signi¢cantly.
VRK genes are expressed, particularly at mid-gestation, in em-
bryo thymus and spleen, but in adult thymus and spleen their
levels are very low. VRK2 is expressed at lower levels than
VRK1 and VRK3 in the mouse embryo. VRK genes play a
role during embryonic development of hematopoiesis.
+ 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
The vaccinia-related kinase (VRK) Ser-Thr protein kinases
have been identi¢ed in the human kinome as a new family,
diverging early from the branch that led to casein kinases [1].
These kinases have homology in their catalytic domain to a
gene in Caenorhabditis elegans that is embryonic lethal [2],
and to genes in Schizosaccharomyces pombe that are impli-
cated in DNA damage repair [3]. The family is composed of
three members, originally identi¢ed by the homology of the
catalytic domain to the same region of the vaccinia virus B1R
kinase [4], a kinase necessary for viral DNA replication. The
human VRK1 protein phosphorylates p53 in Thr-18 [5], and
has an a⁄nity that is well adapted to the intracellular concen-
trations of p53 [6]. Among these kinases, only the subcellular
localization for VRK1 is known; this kinase is nuclear during
interphase [5,7], and dispersed throughout the cell, but not
located on the mitotic spindle or chromatids during mitosis
(F.M. Vega and P.A. Lazo, unpublished). The three VRK
human kinase genes appear to have a ubiquitous expression
in adults, but the levels vary greatly depending on the cell line
type [4]. It has been suggested that these kinases are expressed
at high levels under conditions of proliferation, such as in
regenerating liver or tumor cells [4].
The regulation of p53 plays a major role in the control of
the cell cycle, proliferation and apoptosis [8,9]. P53 mediates
signals that control DNA integrity [10]. Thus, in case of ge-
netic damage, p53 stops the cell cycle to permit its repair or
alternatively, if the DNA damage cannot be repaired, the cell
undergoes apoptosis and thus the organism is protected [9,11].
The tumor suppressor protein p53 is a key molecule in the
integration of cellular responses to many di¡erent types of
stimulation, both in normal conditions and under di¡erent
stress situations [12]. Therefore, the intracellular level of p53
is essential for cell cycle control and induction of apoptosis
[13]. The regulation of the p53 tumor suppressor protein is
mediated by di¡erent types of posttranslational modi¢cations,
such as phosphorylation, acetylation, sumoylation and ubiq-
uitination [14,15]. The p53 protein is regulated by several ki-
nases [16,17] that respond to di¡erent types of activation
[12,18]. Some of the p53 phosphorylations take place in its
N-terminus [5,19], in a region that is required for binding to
its negative regulator mdm-2/hdm-2 [20], preventing their in-
teraction and thus resulting in an increase in p53 stability. The
phosphorylation of Thr-18 is the main regulator of the p53^
mdm2 interaction [21,22]. Recently some new kinases that
phosphorylate p53 in its mdm-2 binding site have been re-
ported [5,6].
In this report we have analyzed the pattern of expression of
the VRK gene family of p53 regulatory kinases during murine
development in the post-gastrulation mouse embryo, particu-
larly in the context of the hematopoietic system. The ubiqui-
tous expression, though at very di¡erent levels, of these genes
suggests that they play a basic role in cell physiology, and
their inactivation is likely to be lethal in the embryo.
2. Materials and methods
2.1. Mice and organs
BALB/c mice were maintained under pathogen-free conditions in
the animal facilities of the ISCIII. Liver, kidney, muscle, thymus and
spleen were dissected from 2-month-old BALB/c mice. Timed preg-
nancies were determined by the observation of the vaginal plug in the
morning after overnight mating (gestation day: 0 days after coitus,
dpc). Single-cell suspensions from blood, yolk sac (YS), liver (10.5^
17.5 dpc), thymus and spleen (13.5^17.5 dpc) were prepared as pre-
viously described [23]. Bone marrow (BM) was £ushed out by injec-
tion of phosphate-bu¡ered saline/2% fetal calf serum with a 25-gauge
needle into the femur of 2-month-old BALB/c mice. Viable cells were
counted by trypan blue exclusion.
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2.2. RNA extraction from organs in murine embryos
Total RNA was extracted from di¡erent microdissected organs and
cell suspensions using the phenol^guanidinium method (Trizol re-
agent, Invitrogen, Carlsbad, CA, USA), followed by ethanol precip-
itation. The RNA (0.2 Wg) was used for cDNA synthesis with Super-
script reverse transcriptase (Invitrogen) according to the manufac-
turer’s instructions.
2.3. PCR ampli¢cation of murine VRK1, VRK2 and VRK3
The presence of RNA speci¢c for VRK1, VRK2 and VRK3 was
determined by semi-quantitative polymerase chain reaction (PCR). A
tenth of the reverse transcription (RT) reaction was used as substrate
for PCR ampli¢cation. For ampli¢cation of murine VRK1 (GenBank
AA815837) we used primers mVRK1A (5P-ATGCCCCGTGTAAA-
AGCAGCTC-3P) and mVRK1B (5P-GAAGTACCTTGGTGTTC-
CTAAG-3P), which amplify a band of 332 nt. The ampli¢cation of
the murine VRK2 (GenBank AA914007) was performed with prim-
ers mVRK2A (5PGGATTTGGTCTGACTGATTTCAAAGG-3P) and
mVRK2B (5P-GGAGTGGCCCCATCCAGGAGGAGTG-3P), which
amplify a band of 382 nt. The ampli¢cation was performed with an
initial cycle at 95‡C for 5 min, followed by 25 cycles consisting of
three steps (95‡C for 40 s, 56‡C for 40 s, and 72‡C for 50 s), and a ¢nal
cycle at 72‡C for 5 min. For murine VRK3 (GenBank BC010473) the
primers used were mVRK3A (5P-TGACGCCTCATGTGTCATCCG-
TTCC-3P) and mVRK3B (5P-TTGTCCTGGTGAATGCCAAAGC-
CG-3P), which amplify a band of 559 nt. The conditions were an
initial cycle at 92‡C for 5 min, 30 cycles (92‡C for 40 s, 58‡C for
40 s, and 72‡C for 40 s) and a ¢nal cycle at 72‡C for 10 min. The
primers and PCR conditions of the L-actin PCR used here to normal-
ize the cDNA content were as described [23]. All the reactions were
performed with Taq DNA polymerase (Promega, Madison, WI, USA)
with 2.5 mM MgCl2. The PCR products were analyzed in a 2% aga-
rose gel. DNA was transferred to a Zeta-Probe (Bio-Rad, San Diego,
CA, USA) membrane and hybridized to the corresponding probe at
high stringency under conditions previously described [24]. The gel
image was analyzed with the Quantity One software using a Bio-
Rad FX Imager. For quanti¢cation suboptimal exposures within the
linear response range were used.
3. Results
3.1. The murine VRK proteins
Of the three murine VRK proteins, only VRK1 has been
partially characterized [7]. The other two were identi¢ed by
their homology to the corresponding human cDNA. The
alignment of the expected three murine proteins with the Clus-
tal W program is shown in Fig. 1. The three VRK proteins
have high homology in their Ser-Thr catalytic domain. Both
VRK1 and VRK2 proteins have the catalytic domain in their
amino-terminus, while in the VRK3 protein it is located at the
carboxy-terminus. The Ser-Thr kinase domain, including the
ATP binding site and the catalytic site, spans a region of
approximately 295 residues (Fig. 1), with an overall homology
of 73% between the three proteins, with half of the residues
identical, and the other half similar. VRK1 has a nuclear
localization signal (NLS) in residues 356^360, consistent
with its nuclear localization by subcellular fractionation [7].
VRK3 also has a bipartite NLS sequence at positions 49^66,
but its subcellular localization in vivo is not known. The
VRK2 protein has a hydrophobic membrane-anchoring re-
gion at the end of its carboxy-terminus, spanning residues
432^453, and two isoforms with and without this anchor are
present in some cell types (S. Blanco, L. Klimcakova and P.A.
Lazo, unpublished). VRK1 and VRK2 diverge in their car-
boxy-terminal regions and have no homology to any other
known domain or protein characteristic. This lack of homol-
ogy also applies to the amino-terminus of VRK3. These di-
vergent regions are likely to be implicated in the regulation of
these Ser-Thr kinases.
3.2. VRK gene expression in developing murine liver
In murine post-gastrulation embryonic development the liv-
er undergoes a massive increase in cell number and size, from
103 cells to 107 total recovered cells per organ [23]. During
this time window a simultaneous process of hematopoiesis
and liver morphogenesis is taking place in the organ [25,26].
From day 13.5, liver hematopoietic precursors are released
and home other hematopoietic niches that become receptive,
such as spleen, thymus, and ¢nally by day 17 the bone mar-
row that becomes the major hematopoietic organ in adult-
hood [26]. We determined the expression of the three VRK
genes in murine embryo liver from days 11.5 to 17.5 (Fig. 2).
 
MVRK1      M--------------------------------------PRVKAAQAGRP    12 
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MVRK2       KLLDQNGG-F-KKLTVLQLGIRMLDVLEYIHENEYVHGDIKAANLLLDFT   177 
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MVRK1       -----------DGKLDFSAVENGSVKTRPASKKRKKEAEESAVCAVEDME   374 
MVRK2       KVQSVHVRTPAQQKVDSPKATRKPANEFPAKFPKKVHRETRARQREEQED   377 
MVRK3       --------------------------------------------------   432 
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MVRK2       TKADVYYYGITIFCLLIFVFLALYFL   503 
 
NLS
NLS
TM 
MVRK3       -----------------------------453        
MVRK1       KKAQK------------------------440        
Fig. 1. Alignment of the three murine VRK Ser-Thr kinases. The
proteins derived from the cDNA were aligned with the Clustal W
program. The conserved Ser-Thr kinase domain is indicated by a
bold bar and includes the ATP binding site and the catalytic
site. NLS represents the nuclear localization signal in VRK1 and
VRK3. TM indicates the transmembrane domain of VRK2. Identi-
cal (asterisks) and similar (dots) amino acid residues are indicated.
GenBank accession numbers: for murine VRK1 (AA815837), VRK2
(AA914007) and VRK3 (NM_133945).
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The three VRK genes are expressed throughout liver develop-
ment with maximal expression between days 11 and 14, while
at day 10.5 only low levels of the transcripts were detected
(not shown). The expression is approximately 10- and 20-fold
higher for VRK1 and VRK3, respectively, than for VRK2. In
both cases, gene expression falls by more than one order of
magnitude by day 14.5 (Fig. 2). The relative levels of VRK1
with respect to VRK3 are similar throughout liver develop-
ment. The levels of VRK2, although reaching a maximum on
the same days, between days 11.5 and 13.5, have a smaller
overall variation. The expression increases again at day 17.5,
and remains positive thereafter (not shown).
3.3. VRK gene expression in hematopoietic embryonic tissues
Peripheral blood was extracted from the embryo umbilical
cord and used for VRK expression analysis from days 10.5 to
17.5. The highest levels were detected at days 10.5 and 11.5
and slowly decreased until day 14.5 followed by a drop of at
least one order of magnitude in the case of VRK1 at day 15.5.
In the case of VRK2 and VRK3 the drops, if any, in level
after day 14.5 are signi¢cantly smaller and the values are very
similar throughout the whole embryonic period (Fig. 3A).
VRK gene expression was also analyzed in thymus and
spleen, between days 13.5 and 17.5. There is always a rela-
tively high expression, particularly for VRK1 and VRK3 in
these locations. As happened in liver and blood, VRK2 sig-
nals are much lower (10-fold). In the two organs there appears
to be a stable level of expression for each VRK gene, regard-
less of their individual expression di¡erences (Fig. 3B).
3.4. Low expression of VRK1 and VRK2 genes in the YS
The extra-embryonic layers of the amnion and YS play an
important nutritional role for the post-implantation embryo.
The YS also supports primitive and de¢nitive erythromyelo-
poiesis at early stages after gastrulation (from 7 to 10 dpc)
until it is replaced by the liver as the major hematopoietic
organ at 11.5 dpc [26]. The YS expresses the three VRK genes
between days 10.5 and 15.5. VKR1 and VKR2 are expressed
at lower levels than VKR3 (diluted 10-fold in the gel shown)
in these samples, and by day 15 there is an important drop in
their expression (Fig. 3C).
3.5. VRK gene expression in murine adult organs
The expression of the three murine kinases, VRK1, VRK2
and VRK3, was studied by RT-PCR in tissues from adult
mice. As shown in Fig. 4, VRK1 and VRK2 expressed clearly
di¡erent levels depending on the tissue. Kidney, muscle and
liver from 2-month-old BALB/c mice highly express the ki-
nases. The adult hematopoietic tissues analyzed here (thymus,
spleen and bone marrow) expressed low levels of VRK1 and
VRK2. On the other hand, VRK3 appears to be expressed
more homogeneously in all tissues tested, except in spleen
where its expression is also decreased. These expression data
were con¢rmed by Northern blot analysis (not shown).
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Fig. 2. VRK gene expression in liver embryonic development. The
samples comprise from day 11 to 17 that includes the period of
massive expansion in liver cells. The exposures shown are longer
than those used for quanti¢cation. The amount of VRK3 PCR
loaded is one tenth of the VRK1 and VRK2. Positive control for
VRK3 is not shown. The exposures shown in the ¢gure do not cor-
respond to those used for quanti¢cation, which were much shorter.
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Fig. 3. VRK gene expression in peripheral blood from embryo um-
bilical cord (A), spleen and thymus (B) and YS (C). The amount of
VRK3 PCR loaded in A and B is one tenth of the VRK1 and
VRK2. The exposures shown in the ¢gure do not correspond to
those used for quanti¢cation, which were much shorter.
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4. Discussion
The expression of VRK genes suggests mostly a common
pattern of expression for the three genes regarding timing and
levels. During murine development the £uctuations in the lev-
els of the three members of the VRK family follow a similar
pattern in liver and peripheral blood. In general there is a
peak of expression that occurs between days 11.5 and 13.5
followed by a signi¢cant drop in the levels, particularly in
peripheral blood. In fetal liver the highest level of expression
corresponded to the time when the liver undergoes a major
expansion in cell number, where the increase corresponds to
very short cell cycles, since there are at least 20 cells doubling
in 3 days.
The expression of VRK1 in liver development, during the
phase of its massive expansion, is consistent with the relatively
higher expression detected in regenerating liver and in hepa-
tomas, suggesting that in this cell type it is associated with the
increase in cell number [4], or with its early hematopoietic
role. However, its high expression in adult liver, where there
is no cell proliferation, suggests a more complex role for these
proteins in cell biology.
The VRK proteins are members of a new signaling pathway
and their targets have not yet been characterized, despite their
presence in almost all cell types tested. One of the protein
targets of the VRK1 and VRK2 kinases is p53, both speci¢-
cally phosphorylate p53 in Thr-18 [5]. The consequence is the
stabilization and accumulation of p53. This e¡ect is likely to
represent a basic mechanism by which p53 is ready to respond
to its signals. For the p53 protein to be functional to be able
to initiate a response to damage, a minimum level of its ac-
tivity has to be preserved in the cell at all times. The mecha-
nism that maintains p53 in its readiness state is very little
known. The VRK proteins are candidates to be a component
of this mechanism, particularly VRK1. Consistent with this
role could be a ubiquitous or near-ubiquitous expression and
a certain degree of redundancy in their activities.
In adult organs the three genes are widely expressed and the
ratio of the three is similar. This suggests that VRK genes are
likely to play a basic role in cell biology. Among these func-
tions, and based on the nature of some of their phosphoryla-
tion targets, they must play a role related to cellular protec-
tion, constituting a system ready for immediate response.
Because of this role as a possible part of cell protection mech-
anisms, they are likely to be candidates for a role as tumor
susceptibility or tumor suppressor genes. This is consistent
with the very high frequency of loss of heterozygosity
(LOH) of markers £anking the VRK1 gene in region 14q32
detected in neuroblastomas [27], nasopharyngeal [28] and co-
lorectal carcinomas [29], and in the blastic crisis of chronic
myelogenous leukemia [30]. LOH £anking the VRK2 locus in
2p14 has been reported in lung [31] and adrenocortical [32]
cancers.
The information on gene expression of VRK genes is also
relevant for the future design of knock-out strategies to de-
termine the individual VRK gene role, since there is a poten-
tial risk of redundancy. Furthermore, because of their expres-
sion during early phases of liver development, there is a
signi¢cant risk that knock-out animals will be non-viable, as
in C. elegans [2], unless they are generated as conditional
knock-out mice and the genes are induced after liver develop-
ment.
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